Pfizer
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Pfizer sits in the top decile of US sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count).
Pfizer: 1,845 sponsored US clinical trials, 106 recruiting.
Pfizer sponsors 1,845 registered US clinical trials on ClinicalTrials.gov, 106 of them currently recruiting, and 1,335 completed. 504 of these trials are in Phase 3-4 (later-stage) and 1,173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 44 trials.
Top-decile sponsor footprint
Pfizer ranks in the top decile of sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,335 of 1,673 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,845 total, page 19 of 37
Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug Levels
NCT01749085
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
NCT01730339
A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus
NCT01792635
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
NCT01719380
A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
NCT01352793
A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers
NCT01740609
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
NCT01712074
Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia
NCT01769274
Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis
NCT01470612
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
NCT01757756
A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162
NCT01691274
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
NCT01599806
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
NCT01673178
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
NCT01595438
Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia
NCT01603394
Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet
NCT01789606
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
NCT01543087
A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers
NCT01677065
Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years
NCT01706367
Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation
NCT01677039
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
NCT01562899
Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)
NCT01643928
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
NCT01564784
Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis
NCT01602341
A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers
NCT01637285
Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years
NCT01643941
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
NCT01664923
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT01577381
A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women
NCT01634789
A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis
NCT01458574
A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
NCT01628107
A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition
NCT01557244
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
NCT01576406
A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects
NCT01720537
NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)
NCT01654250
Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis
NCT01652885
Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
NCT01592240
Benzonatate Dose Tolerance Study
NCT01690975
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT01546038
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
NCT01525550
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis
NCT01458951
A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects
NCT01616277
A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain
NCT01571362
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
NCT01396148
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
NCT01628120
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
NCT01543698
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.
NCT01574703
A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)
NCT01603264
Relative Bioavailability Study
NCT01602887
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
NCT01499277
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 703 |
| Phase 2 | 470 |
| Phase 3 | 411 |
| Phase 4 | 93 |
Therapeutic Areas
What is open in the Pfizer pipeline
106 recruiting of 1,845 indexed (6% open); 1,335 completed (72%).
Phase mix: 504 late (III/IV) vs 1,173 early (I/II) (early-phase heavy).
Top condition: Healthy (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Pfizer: open-pipeline peers nationwide
Peers matched on 1,845 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,845 trials (± recruiting share)
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- Duke University · 1,725 trials · 11% recruiting
- University of California, San Francisco · 1,713 trials · 16% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Pacira Pharmaceuticals · 6% recruiting · 88 trials
- BioDelivery Sciences International · 6% recruiting · 17 trials
- Colgate Palmolive · 6% recruiting · 51 trials
- Durham VA Medical Center · 6% recruiting · 17 trials
Related
What to do with this Pfizer page
1,845 registered trials is a research-attention snapshot, not an endorsement of Pfizer or any single study.
- 106 of Pfizer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Pfizer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Pfizer pipeline card: 1,845 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.